NCT07919678ClinicalTrials.gov
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)
In brief
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…
Phase 3656 participants sought40 sites2 countries
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07919678Open this record at ClinicalTrials.govSynced 2 weeks ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 3 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 40 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.
How this score is built
- Enrolment28/40
656 participants (target)
- Site count19/25
40 sites
- Country count7/15
2 countries
- Planned duration7/10
Planned over about 24 months
- Sponsor scale10/10
Pfizer has led 630 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
Conditions
- Obesity
- Overweight
- Osteoarthritis of the Knee
Eligibility
| Sex | All |
|---|---|
| Ages | 18 Years – No maximum |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 3 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 656 participants sought |
Sponsor and collaborators
- Pfizer Sponsor
Arms and interventions
- PlaceboPLACEBO_COMPARATOR
Participants will receive placebo as subcutaneous injection
- Arm 1: Berobenatide Once MonthlyEXPERIMENTAL
Participants will receive berobenatide by subcutaneous injection.
- Arm 2: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
- Arm 3: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
Interventions
- Drug Berobenatide
Subcutaneous Injection
- Other Placebo
Subcutaneous Injection
Outcome measures
Primary outcome
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score
Time frame Baseline and Week 52
Secondary outcome
Percent change from baseline in Body Weight
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in High-Sensitivity C-Reactive Protein
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in WOMAC Physical Function Subscale score
Time frame Baseline and Week 52
Secondary outcome
Percentage of participants with ≥50% reduction in the WOMAC pain subscale score
Time frame Baseline and Week 52
Secondary outcome
Percentage of participants with ≥30% reduction in the WOMAC pain subscale score
Time frame Baseline and Week 52
Secondary outcome
Proportion of participants with utilization of protocol specified pain medication during the washout period
Time frame Baseline and Week 52
Secondary outcome
Amount of protocol specified pain medication during the washout period
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in WOMAC stiffness score
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in WOMAC total score
Time frame Baseline and Week 52
Secondary outcome
Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score
Time frame Baseline and Week 52
Secondary outcome
Proportion of participants meeting OMERACT-OARSI
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in Average Pain Intensity-Numerical Rating Score
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in Worst Pain Intensity -Numerical Rating Score
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in SF-36 domain scales and component summary scales
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in Body Weight
Time frame Baseline and Week 52
Secondary outcome
Change from Baseline in Body Mass Index
Time frame Baseline and Week 52
Secondary outcome
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Time frame Baseline and Week 52
Secondary outcome
Number of Participants with Serious Adverse Events (SAE)
Time frame Baseline and Week 52
Secondary outcome
Number of Participants with AE leading to permanent discontinuation from study intervention or study
Time frame Baseline and Week 52
Secondary outcome
Number of Participants with Adverse Events of Special Interest (AESI)
Time frame Baseline and Week 52
Secondary outcome
Number of Participants with Clinical laboratory abnormalities
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in timed walking distance at Week 52
Time frame Baseline and Week 52
Secondary outcome
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function
Time frame Baseline and Week 52
Secondary outcome
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain
Time frame Baseline and Week 52
Secondary outcome
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function
Time frame Baseline and Week 52
Secondary outcome
Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in WPAI:GH Work productivity loss score
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in WPAI:GH Activity impairment score
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in Systolic Blood Pressure (SBP)
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in Diastolic Blood Pressure (DBP)
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in Total Cholesterol
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in High-density lipoprotein cholesterol (HDL-C)
Time frame Baseline and Week 52
Secondary outcome
Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in Non-HDL Cholesterol
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol
Time frame Baseline and Week 52
Secondary outcome
Change from baseline in Triglycerides
Time frame Baseline and Week 52
Dates
| Start date | October 26, 2026 (actual) |
|---|---|
| Primary completion | August 22, 2028 (estimated) |
| Completion | October 10, 2028 (estimated) |
| First posted | November 5, 2026 (actual) |
| Last updated | November 5, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | October 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
7 sites are recruiting
Canada
| Facility | City | State or region | Status |
|---|---|---|---|
| Bluewater Clinical Research Group Inc. | Sarnia | Ontario | Not yet recruiting |
United States
| Facility | City | State or region | Status |
|---|---|---|---|
| Albuquerque Clinical Trials, Inc. | Albuquerque | New Mexico | Not yet recruiting |
| Charlottesville Medical Research Center, LLC | Charlottesville | Virginia | Not yet recruiting |
| Northwestern University Feinberg School Of Medicine | Chicago | Illinois | Not yet recruiting |
| Great Lakes Clinical Trials, LLC dba Flourish Research | Chicago | Illinois | Not yet recruiting |
| Northwestern Medicine | Chicago | Illinois | Not yet recruiting |
| Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG) | Chicago | Illinois | Not yet recruiting |
| Northwestern Memorial Hospital, Investigational Drug Service | Chicago | Illinois | Not yet recruiting |
| Clinical Research of West Florida, Inc. | Clearwater | Florida | Not yet recruiting |
| Skylight Health Research | Colorado Springs | Colorado | Not yet recruiting |
| Mercy Family Clinic | Dallas | Texas | Not yet recruiting |
| Universal Axon Clinical Research LLC | Doral | Florida | Recruiting |
| Altoona Center For Clinical Research | Duncansville | Pennsylvania | Recruiting |
| Headlands Research California, LLC | Escondido | California | Not yet recruiting |
| Profound Research LLC | Farmington Hills | Michigan | Recruiting |
| Cedar Health Research | Fort Worth | Texas | Not yet recruiting |
| Novant Health Granite Quarry Internal Medicine (knee x-ray) | Granite Quarry | North Carolina | Not yet recruiting |
| BRCR Global Louisiana | Gretna | Louisiana | Not yet recruiting |
| JCCT-JUNO NW Houston | Houston | Texas | Not yet recruiting |
| Westside Center for Clinical Research | Jacksonville | Florida | Not yet recruiting |
| Activian Clinical Research | Kingwood | Texas | Not yet recruiting |
| Renstar Medical Research | Lady Lake | Florida | Not yet recruiting |
| Monroe Biomedical Research | Monroe | North Carolina | Recruiting |
| AMR Clinical | Norman | Oklahoma | Not yet recruiting |
| Renstar Medical Research | Ocala | Florida | Not yet recruiting |
| Prospective Research Innovations Inc. | Rancho Cucamonga | California | Not yet recruiting |
| Accellacare - Salisbury | Salisbury | North Carolina | Not yet recruiting |
| Consano Clinical Research, LLC | Shavano Park | Texas | Not yet recruiting |
| Revive Research Institute, Inc. | Sterling Heights | Michigan | Recruiting |
| Clinical Research Atlanta | Stockbridge | Georgia | Not yet recruiting |
| Clinical Research of West Florida, Inc. | Tampa | Florida | Not yet recruiting |
| AMR Clinical | Tempe | Arizona | Not yet recruiting |
| DM Clinical Research | Tomball | Texas | Not yet recruiting |
| Solace Clinical Research | Tustin | California | Not yet recruiting |
| Velocity Clinical Research, Waco | Waco | Texas | Not yet recruiting |
| Elevate Clinical Research | Wichita | Kansas | Not yet recruiting |
| Delaney Radiologist | Wilmington | North Carolina | Recruiting |
| Accellacare | Wilmington | North Carolina | Recruiting |
| North Georgia Internal Medicine | Woodstock | Georgia | Not yet recruiting |
| North Georgia Clinical Research, LLC | Woodstock | Georgia | Not yet recruiting |
Study documents
No documents are linked in this registry record.
Changes over time
No changes have been recorded since we first ingested this record.
A change is recorded each time the sponsor updates the registry record. Status, dates, enrolment and sites appear here as they move.